Cytokinetics, Incorporated (CYTK)

Market Cap	7.67B
Revenue (ttm)	87.21M
Net Income (ttm)	-751.94M
Shares Out	122.26M
EPS (ttm)	-6.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,313,652
Open	62.93
Previous Close	62.20
Day's Range	62.10 - 63.70
52-Week Range	29.31 - 69.33
Beta	0.59
Analysts	Strong Buy
Price Target	78.94 (+25.86%)
Earnings Date	Nov 5, 2025

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle tropo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2004
• Employees: 498
• Stock Exchange: NASDAQ
• Ticker Symbol: CYTK
• Website: https://www.cytokinetics.com

Financial Performance

In 2024, Cytokinetics's revenue was $18.47 million, an increase of 145.34% compared to the previous year's $7.53 million. Losses were -$589.53 million, 12.0% more than in 2023.

Analyst Summary

According to 16 analysts, the average rating for CYTK stock is "Strong Buy." The 12-month stock price target is $78.94, which is an increase of 25.86% from the latest price.

Price Target

$78.94

(25.86% upside)

Analyst Consensus: Strong Buy